CAMBRIDGE, Mass., May 30, 2025 /PRNewswire/ Myeloid Therapeutics, a clinical-stage immunology company, is presenting two groundbreaking posters this week at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, highlighting its lead in vivo mRNA CAR therapies, MT-303 and MT-302.
This marks a significant milestone in the field of RNA-based immuno-oncology. Myeloid is pushing beyond the limits of traditional CAR therapies by removing the need for complicated ex vivo manipulation and instead reprogramming immune cells directly inside the body using mRNA encapsulated in lipid nanoparticles (LNPs). This approach aims to deliver potent, tumor-specific immune activation in patients with advanced solid tumors.
“Our presentations at ASCO demonstrate the clinical translation of our proprietary mRNA-LNP platform for in vivo immune cell engineering,” said Daniel Getts, PhD, CEO and Co-founder of Myeloid Therapeutics. “With MT-302 and MT-303, we are pushing beyond the limits of traditional CAR therapies—removing the need for often complicated ex vivo manipulation while delivering potent, tumor-specific immune activation in patients with advanced solid tumors.”
“These data show that we can deliver repeated doses of LNP-mRNA in patients demonstrating that CAR-programmed myeloid cells can penetrate solid tumors and alter the tumor microenvironment (TME), which opens up multiple avenues for potential clinical benefit moving forward,” said Matt Maurer, MD, Chief Medical Officer of Myeloid Therapeutics. “The results offer early validation of Myeloid’s platform technologies, and could ultimately change how solid tumors are treated, offering patients a more accessible, potentially more tolerable, and highly targeted therapy option in the future without the burdens associated with traditional cell therapies.”
Key Highlights from ASCO Presentations:
- MT-302 (TROP2-Targeted mRNA CAR Therapy): The first intravenously delivered mRNA-based CAR therapy to enter clinical trials! Preliminary findings from the Phase 1 study demonstrate selective CAR expression in myeloid cells and increased pro-inflammatory gene signatures.
- MT-303 (GPC3-Targeted mRNA CAR Therapy): An innovative in vivo CAR therapy designed to reprogram myeloid cells to recognize and destroy GPC3+ tumor cells in hepatocellular carcinoma (HCC) and other GPC3+ solid tumors.
This innovative platform could redefine how solid tumors are treated, offering a more accessible, potentially more tolerable, and highly targeted therapy option for patients.
Source:
https://www.prnewswire.com/news-releases/myeloid-therapeutics-unveils-first-in-human-in-vivo-mrna-car-data-marking-a-breakthrough-in-rna-based-immuno-oncology-at-the-2025-asco-annual-meeting-302469096.html
About PackGene
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
